A citation-based method for searching scientific literature

Carol Aghajanian, Stephanie V Blank, Barbara A Goff, Patricia L Judson, Michael G Teneriello, Amreen Husain, Mika A Sovak, Jing Yi, Lawrence R Nycum. J Clin Oncol 2012
Times Cited: 788



Jonathan A Ledermann, Andrew C Embleton, Fharat Raja, Timothy J Perren, Gordon C Jayson, Gordon J S Rustin, Stan B Kaye, Hal Hirte, Elizabeth Eisenhauer, Michelle Vaughan, Michael Friedlander, Antonio González-Martín, Daniel Stark, Elizabeth Clark, Laura Farrelly, Ann Marie Swart, Adrian Cook, Richard S Kaplan, Mahesh K B Parmar. Lancet 2016
Times Cited: 131




List of shared articles



Times cited

Stiffness increases with myofibroblast content and collagen density in mesenchymal high grade serous ovarian cancer.
Virginie Mieulet, Camille Garnier, Yann Kieffer, Thomas Guilbert, Fariba Nemati, Elisabetta Marangoni, Gilles Renault, Foucauld Chamming's, Anne Vincent-Salomon, Fatima Mechta-Grigoriou. Sci Rep 2021
2

The systemic treatment of recurrent ovarian cancer revisited.
T Baert, A Ferrero, J Sehouli, D M O'Donnell, A González-Martín, F Joly, J van der Velden, P Blecharz, D S P Tan, D Querleu,[...]. Ann Oncol 2021
5

Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
Angeles Alvarez Secord, David M O'Malley, Anil K Sood, Shannon N Westin, Joyce F Liu. Gynecol Oncol 2021
0

Clinical benefit of systemic therapies for recurrent ovarian cancer-ESMO-MCBS scores.
K E Broekman, M van Kruchten, H van Tinteren, C Sessa, M Jalving, A K L Reyners. ESMO Open 2021
0

Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial.
J A Ledermann, A C Embleton-Thirsk, T J Perren, G C Jayson, G J S Rustin, S B Kaye, H Hirte, A Oza, M Vaughan, M Friedlander,[...]. ESMO Open 2021
1

Recent advancements of antiangiogenic combination therapies in ovarian cancer.
Daniel An, Susana Banerjee, Jung-Min Lee. Cancer Treat Rev 2021
1

The role of vascular endothelial growth factor inhibitors in the treatment of epithelial ovarian cancer.
Alexander D Murphy, Robert D Morgan, Andrew R Clamp, Gordon C Jayson. Br J Cancer 2021
0

Overview of imaging findings associated with systemic therapies in advanced epithelial ovarian cancer.
Ezgi Guler, Daniel A Smith, Bhanusupriya Somarouthu, Rahul Gujrathi, Nikhil H Ramaiya, Sree Harsha Tirumani. Abdom Radiol (NY) 2020
2

Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
Ling Wang, Qi Wang, Yangchun Xu, Manhua Cui, Liying Han. Curr Drug Targets 2020
5

Targeted therapy clinical trials in ovarian cancer: improved outcomes by gene mutation screening.
Quan Guo, Qing Yang, Jun Li, Guipeng Liu, Igor Nikoulin, Steve Jia. Anticancer Drugs 2020
3

Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218.
Angeles Alvarez Secord, Kirsten Bell Burdett, Kouros Owzar, David Tritchler, Alexander B Sibley, Yingmiao Liu, Mark D Starr, J Chris Brady, Heather A Lankes, Herbert I Hurwitz,[...]. Clin Cancer Res 2020
11

Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial.
Robert D Morgan, Susana Banerjee, Marcia Hall, Andrew R Clamp, Cong Zhou, Jurjees Hasan, Cecilia Orbegoso, Sarah Taylor, Jonathan Tugwood, Alexander R Lyon,[...]. Gynecol Oncol 2020
2

Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial.
Robert L Coleman, Katelyn F Handley, Robert Burger, Graziela Zibetti Dal Molin, Robert Stagg, Anil K Sood, Kathleen N Moore. Gynecol Oncol 2020
9

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Jacobus Pfisterer, Catherine M Shannon, Klaus Baumann, Joern Rau, Philipp Harter, Florence Joly, Jalid Sehouli, Ulrich Canzler, Barbara Schmalfeldt, Andrew P Dean,[...]. Lancet Oncol 2020
31

Real world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in the United Kingdom prior to poly-ADP ribose polymerase inhibitors.
Rosemary Lord, Jyoti Rauniyar, Tamsin Morris, Orlaith Condon, Rachel Jones, Rowan Miller, Marcia Hall, Fiona Lofts, Rosalind M Glasspool, Emma Hudson. Int J Gynecol Cancer 2020
2